1. Scrip
  2. >>Focus On Asia
  3. >>China

China Joins U.S. In Common Application Format To Simplify Patent Applications

 
• By Brian Yang

In a refreshed effort towards international patent harmonization, China will soon initiate a common application format, easing registration requirements for companies entering the country as well as new domestic players looking outward.

BEIJING – China’s State Intellectual Property Office (SIPO) has joined the U.S., EU, Japan, and Korea to become the fifth participant in an international effort to streamline patent applications.

SIPO issued guidelines for a common application format on its website June 27, listing details on how to submit a...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from China

China’s Therapeutic mRNA Vaccine Pipeline For Oncology The Largest Globally

 
• By Xu Hu

Nearly half of the mRNA-based therapeutic vaccines for cancer in the R&D pipeline globally are from Chinese companies, although financing activities in the area have been relatively quiet so far this year in China compared with 2020-23.

Biokin/BMS, Genfleet/Verastem’s Drug Candidates Impress At WCLC

 
• By Dexter Jie Yan

With data generated from China-only trials and consistency issues lingering, Chinese drug makers presented impressive results from early-stage studies of their assets at the World Conference on Lung Cancer annual conference.

The Rise In China Deals: How International Biopharma Is Turning To China For Innovation

 
• By Joseph Haas, Mary Jo Laffler, and Nancy Pham

The rapid growth of Chinese biopharmas has led to increased dealmaking with the US and Europe, but that could be stifled by a potential new Trump Administration policy.

Hengrui’s Lucrative Dealmaking Year Continues With Braveheart

 
• By Joseph Haas

Deal Snapshot: Hengrui makes its third potential billion-dollar licensing deal of 2025, this time sending rights to Phase III hypertrophic cardiomyopathy drug HRS-1893 to Braveheart.

More from Focus On Asia

Biokin/BMS, Genfleet/Verastem’s Drug Candidates Impress At WCLC

 
• By Dexter Jie Yan

With data generated from China-only trials and consistency issues lingering, Chinese drug makers presented impressive results from early-stage studies of their assets at the World Conference on Lung Cancer annual conference.

The Rise In China Deals: How International Biopharma Is Turning To China For Innovation

 
• By Joseph Haas, Mary Jo Laffler, and Nancy Pham

The rapid growth of Chinese biopharmas has led to increased dealmaking with the US and Europe, but that could be stifled by a potential new Trump Administration policy.

Indigenization, AI Drive ICMR, Gennova, Zydus Vaccine Efforts In India

 
• By Vibha Ravi

Indian firms are upping indigenization, exploring AI application and expanding use of technology platforms like self-amplifying mRNA to develop vaccines against age-agnostic diseases like malaria, dengue, flu and Nipah encephalitis